Earnings Releases·Nov 4, 2026, 6:44 AM ET

Perrigo — Third Quarter 2026 Earnings Summary

Reported net sales declined 5.2% year-over-year to $989 million, while Core adjusted diluted EPS fell 9.0% to $0.61; reported diluted EPS was negative $0.10.
Full-year 2026 All In adjusted EPS outlook was raised to $2.25–$2.45 (previously $2.00–$2.30), though net sales growth guidance was lowered to a 5.7%–4.6% decline.
Executed a strategic divestiture of the Infant Formula business for up to $175 million, with a related impairment loss of $275.0–$375.0 million expected in Q4 2026.
Returned $40 million to shareholders via dividends in the quarter; cash and cash equivalents stood at $437 million against $3.3 billion in total debt.
The "Three-S" plan continues to drive progress, with management targeting a more focused consumer self-care profile to enhance margins and support deleveraging.